The 7th Dermatology Drug Development Summit Europe is a premier three-day industry event designed for senior leaders, clinical scientists, regulatory experts and commercial strategists shaping the ...

The agreement – which has been valued at up to $1.15 billion – is the strongest signal yet of Hims & Hers' aspirations to grow into a global health player, with the addition of Eucalyptus giving it a ...

The FDA plans to adopt a new policy that will do away with the default requirement to base regulatory filings for new medicines on two pivotal trials, according to Commissioner Marty Makary.

The new NICE guidance recommends that most people should now be offered metformin along with an SGLT-2 inhibitor from the start, while also advising that they get a slow-release formulation of ...

Managing bipolar I disorder (BD-I) is a long-term commitment, and factors such as symptoms and side effects influence ...

The long months without stable leadership at the CDC in the US look set to continue, as the Trump administration confirms that NIH Director Jay Bhattacharya will step in as acting director of the ...

The agreement gives MSD (known as Merck & Co in the US and Canada) access to the Mayo Clinic Platform architecture – which covers de-identified laboratory results, medical imaging, clinical notes, ...

Traditional virtual engagement often forces patients into a corporate mould – a 60-minute, high-pressure web meeting where the loudest voice dominates and key insights are lost to language or time ...

For the last three years, Bayer has been implementing a new strategy for its oncology development, a strategy that led to multiple approvals, as well as a number of promising new programmes added to ...

The FDA has started a priority review of iberdomide as an add-on to Johnson & Johnson and Genmab's anti-CD38 antibody Darzalex (daratumumab) and dexamethasone, a standard regimen for relapsed or ...

Following his return from San Francisco and the JP Morgan Healthcare conference last month, editor-in-chief Jonah Comstock ...

In its new update, Moderna said that it had held a meeting with the FDA's Center for Biologics Evaluation and Research (CBER) and agreed on a "revised regulatory approach" that has allowed the review ...